SlideShare ist ein Scribd-Unternehmen logo
1 von 78
A New Perspective onA New Perspective on
HyponatremiaHyponatremia
by Steve Chenby Steve Chen
Director of Nephrology,
Shin-Chu Branch of Taipei Veterans General Hospital
SodiumSodium
Reference Range:
136 – 145 meq/L
SodiumSodium
Hyponatremia is Na+
< 135 meq/L
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 Serum NaSerum Na++
< 135 meq/L< 135 meq/L
– Symptoms due to brain edema:Symptoms due to brain edema:
headache & vomiting ifheadache & vomiting if NaNa++
< 120< 120
meq/Lmeq/L
– CNS symptoms:CNS symptoms:
convulsions ifconvulsions if NaNa++
< 113 meq/L< 113 meq/L
– CV symptoms:CV symptoms:
CV collapse ifCV collapse if Na < 100 meq/LNa < 100 meq/L
Hyponatremia
HyponatremiaHyponatremia
Causes an osmotic fluid shift from
plasma into brain cells
Hyponatremic encephalopathyHyponatremic encephalopathy
 Hospital acquired:
SIADH
Post-operative state: 3-4 L hypotonic fluid
in 2 days in female  fatal
Encephalitis in children: fatal
 Risk factors:
Children : non-osmotic stimuli of ADH
↑brain/intracranial volume
Female: sex steroid inhibit
brain adaptation Hypoxemia
Hyponatremic encephalopathyHyponatremic encephalopathy
Outpatient :
Medications
Psychogenic polydipsia
Water
intoxification in infants
Marathon runners
Hip fracture
S/P colonoscopy : ADH↑from
bowel manipulation + polyethelene glycol for bowel preparation
Recreational drug:
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 Pathophysiology: CNSPathophysiology: CNS
– Water shifts into brain cellsWater shifts into brain cells
– ApathyApathy –– Altered ConsciousnessAltered Consciousness
– AgitationAgitation –– ConvulsionsConvulsions
– HeadacheHeadache –– ComaComa
– Risk of brain damage > during treatmentRisk of brain damage > during treatment
– Cerebral demyelination syndrome(CDS)Cerebral demyelination syndrome(CDS)
Hyponatremia
Cerebral Demylination SyndromeCerebral Demylination Syndrome
CDSCDS
risk factorsrisk factors
 Development of Hypernatremia
 ↑S-Na > 25 meq /L in 48Hrs
 Hypoxemia
 Hypokalemia
 Mal-nutrition
 Severe liver disease
 Alcoholism
 Severe burns
 Cancer
 U osm ≤ 150 Kg/L
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 Serum OsmolalitySerum Osmolality
– Number of osmoles (osmotically activeNumber of osmoles (osmotically active
particles) in the serumparticles) in the serum
– Normal rangeNormal range
 275 to 295 mosm/L275 to 295 mosm/L
Fluid Balance
2[Serum Na+
] + ------------ + ------------
Glucose BUN
18 2.8
ELECTROLYTE DISORDERSELECTROLYTE DISORDERS
HyponatremiaHyponatremia
Flow of D.D.Flow of D.D.
Plasma
Osmolality
Normal (275-295)
Isotonic
hyponatremia
Low (< 275)
Hypotonic
hyponatremia
High (> 295)
Hypertonic
hyponatremia
Hypovolemic Hypervolemic Euvolemic
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypertonicHypertonic HyponatremiaHyponatremia (P(Posmosm > 295)> 295)
– Large quantities of solute in ECFLarge quantities of solute in ECF
– Water moves from ICF ECFWater moves from ICF ECF
– HyperglycemiaHyperglycemia most common causemost common cause
 Each 100 mg/dl plasma glucose will serumEach 100 mg/dl plasma glucose will serum
NaNa++
by 1.6 meq/Lby 1.6 meq/L
– TreatmentTreatment
 Volume replacementVolume replacement
Hyponatremia, hypertonic
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 IsotonicIsotonic HyponatremiaHyponatremia (P(Posmosm 275 - 295)275 - 295)
– ““PseudohyponatremiaPseudohyponatremia””
– Artifact in serum NaArtifact in serum Na++
measurementmeasurement
 2° High levels of plasma proteins and lipids2° High levels of plasma proteins and lipids
– Etiology:Etiology:
 HyperlipidemiaHyperlipidemia
 HyperproteinemiaHyperproteinemia
Hyponatremia, isotonic
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypotonicHypotonic HyponatremiaHyponatremia (P(Posmosm < 275)< 275)
Plasma Osmolality
Normal (275-295)
Isotonic
hyponatremia
Low (< 275)
Hypotonic
hyponatremia
High (> 295)
Hypertonic
hyponatremia
Hypovolemic Hypervolemic Euvolemic
Hyponatremia, hypotonic
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypovolemicHypovolemic HyponatremiaHyponatremia
– RenalRenal NaNa++
lossloss
 Urine NaUrine Na++
> 20 meq/L> 20 meq/L
 Etiology:Etiology:
– Diuretic useDiuretic use
– Salt-wasting nephropathy (renal tubular acidosis, chronicSalt-wasting nephropathy (renal tubular acidosis, chronic
renal failure, interstitial nephritis)renal failure, interstitial nephritis)
– Osmotic diuresis (glucose, urea, mannitol,Osmotic diuresis (glucose, urea, mannitol,
hyperproteinemiahyperproteinemia
– Mineralocorticoid (aldosterone) deficiencyMineralocorticoid (aldosterone) deficiency
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypovolemicHypovolemic HyponatremiaHyponatremia
– ExtrarenalExtrarenal NaNa++
lossloss
 Urine NaUrine Na++
< 20 meq/L< 20 meq/L
 Etiology:Etiology:
– Volume replacement with hypotonic fluidsVolume replacement with hypotonic fluids
– GI loss (vomiting, diarrhea, fistula, tube suction)GI loss (vomiting, diarrhea, fistula, tube suction)
– Third-space loss (burns, hemorrhagic pancreatitis,Third-space loss (burns, hemorrhagic pancreatitis,
peritonitis)peritonitis)
– Sweating (cystic fibrosis)Sweating (cystic fibrosis)
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypovolemicHypovolemic HyponatremiaHyponatremia
– TreatmentTreatment
 Re-expansion of ECF withRe-expansion of ECF with isotonic salineisotonic saline
 Correction of underlying disorderCorrection of underlying disorder
To calculate Na deficitTo calculate Na deficit
Sodium deficit = total body water X
(desired Na - present Na)
TBW = body wt x 0.6 males
0.5 females
Sodium DeficitSodium Deficit
 Na deficit= Vd of plasma Na x Na deficit per liter﹝ ﹞
 Vd of plasma Na = TBWa = 0.5 x LBW if﹝ ﹞
female =0.6 x LBW if man
 60Kg woman, Thiazide 5 days, acute confusion,
plasma Na = 108meq/L. If Na =120 is safe,﹝ ﹞ ﹝ ﹞
sodium deficit= 0.5x 60x﹙120-108 =360﹚
 Urine Na> 40meq/L indicates Normovolemia
restored
 NS supplied for fear of postsupply overdiuresis
Post-N/S diuresis: turn off ADHPost-N/S diuresis: turn off ADH
U osm <100 mOsm
Initial rate before P-Na targeted:
ongoing free
water loss =
UV x [ 1-( UNa+UK / PNa+PK ) ]
Later rate after P-Na targeted:
free
water loss
= UV x [ 1-( UNa+UK-oral Na+K-IV
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 EuvolemicEuvolemic Hyponatremia(1)Hyponatremia(1)
– SIADHSIADH
 Hypotonic hyponatremiaHypotonic hyponatremia
 Inappropriately elevated urine osmolality (usually > 200Inappropriately elevated urine osmolality (usually > 200
mosm/kg)mosm/kg)
 Elevated urine NaElevated urine Na++
(> 20 meq/L)(> 20 meq/L)
 Clinical euvolemiaClinical euvolemia
 Normal adrenal, renal, cardiac, hepatic, and thyroid functionNormal adrenal, renal, cardiac, hepatic, and thyroid function
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 EuvolemicEuvolemic Hyponatremia(2)Hyponatremia(2)
– Etiology:Etiology:
 HypothyroidismHypothyroidism
 Pain, stress, nausea, psychosis (stimulates ADH)Pain, stress, nausea, psychosis (stimulates ADH)
 Drugs: ADH, nicotine, sulfonylureas, morphine,Drugs: ADH, nicotine, sulfonylureas, morphine,
barbs, NSAIDS, APAP, Carbamazepine,barbs, NSAIDS, APAP, Carbamazepine,
Phenothiazines, TCAs, Colchicine, Clofibrate,Phenothiazines, TCAs, Colchicine, Clofibrate,
Cyclophosphamide, Isoproterenol, Tolbutamide,Cyclophosphamide, Isoproterenol, Tolbutamide,
MAOIsMAOIs
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 EuvolemicEuvolemic Hyponatremia(3)Hyponatremia(3)
– Etiology:Etiology:
 Water intoxication (psychogenic polydipsia)Water intoxication (psychogenic polydipsia)
 Glucocorticoid deficiencyGlucocorticoid deficiency
 Positive pressure ventilationPositive pressure ventilation
 PorphyriaPorphyria
 Essential (reset osmostat orEssential (reset osmostat or sick cell syndromesick cell syndrome))
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 Treatment of Severe Hyponatremia(4)Treatment of Severe Hyponatremia(4)
– Indications:Indications:
 Serum NaSerum Na++
< 120 meq/L< 120 meq/L
 Rapid development ( NaRapid development ( Na++
> 0.5 meq/L/hr)> 0.5 meq/L/hr)
 Patient in extremis (coma, seizures)Patient in extremis (coma, seizures)
– 3% Saline Solution (513 meq/L) @3% Saline Solution (513 meq/L) @ 25 - 10025 - 100
ml/hrml/hr
 NaNa++
should not exceed 0.5 – 1.0 meq/L/hrshould not exceed 0.5 – 1.0 meq/L/hr
Time Classification of SIADH-Time Classification of SIADH-
HyponatremiaHyponatremia
Duration Clinical
setting
Risk Therapy
Acute <48Hr Post-
operative
Brain cell
swelling
↑﹝Na by up﹞
to 5meq/L/H
Chronic Unknown
Or > 48Hr
Many Cerebral
demyelination
syndrome
↑﹝Na﹞
<0.33meq/L/
H
Therapy for SIADHTherapy for SIADH
 Aggressive Tx only for Pts with coma/seizure:
↑ Na up to 5meq/L to control CNS S/S; then﹝ ﹞
↑ Na 8meq/L/D﹝ ﹞≦
 Slow correction when brain cell size normal
↑ Na 8meq/L/D to prevent CDS﹝ ﹞≦ 3%
NaCl 1cc/Kg/Hr= ↑ Na 1meq/L/Hr﹝ ﹞
 Even slower correction if manutrition or
hypercatabolic state(poor availability of K or
organic osmoles
SIADH with chronic hyponatremiaSIADH with chronic hyponatremia
A 50Kg,SIADH due to tumor, plasma
Na 120meq/L, asymptomatic﹝ ﹞
TBW=30L; ICF 20L
Total ICF osmoles normally=20x2x140=5600
If ICF osmoles unchanged,
ICF=5600/2x120=23.2L
Time(hr)=140-120/0.5=40Hr
 Therapeutic goal: To lose 3L of EFW within 40Hr
Treatment guidelinesTreatment guidelines
Administration of oral or IV Na+
(3%)
Supplements
Encourage foods high in Na+
Fluid restriction
Monitor Neurological Status
Normovolemic hyponatremia:V2 antagonist
– Vaprisol (conivaptan) – IV infusion
– Samsca (tolvaptan) - PO
Renal water channels: AQPRenal water channels: AQP
 Aquaporins: AQP 0 ~ 12
 AQP 0: Cataract
 AQP 1 in proximal & thin descending LOH:
re-absorption of most filtered fluid= partial
NDI
 AQP 2 in apical of collecting duct: urine
concentration= NDI
 AQP 3 & 4 in baso-lateral of collecting duct:
 AQP 5: SS
 AQP 7 in apical of S3 proximal: 10% as
water route; glycerol re-absorption
 AQP 11 in intracellular vesicles: PCKD
Sei Sasaki: Tokyo Medical and Dental
AQP 2 binding protein complexAQP 2 binding protein complex
Trafficking of AQP2
Mis-routing to baso-lateral membrane
instead of apical
SPA-1: a GTP-ase activating protein for
Rap1
Cytoskeleton protein actin
Sei Sasaki: Tokyo Medical and Dental
University
Urinary concentration modulationUrinary concentration modulation
↑
c AMP
AQP2 trafficking
and expression
Post-3%N/S free water diuresisPost-3%N/S free water diuresis
 Psychogenic polydipsia
 DC of DDAVP
 Water intoxification in infants
 Hypotonic fluid plus DDAVP for
overcorrection of hyponatremia
 Case:
70Kg, TBW 35, S-Na 110meq/L
1L 3% NaCl  11.2 meq/L↑
by closed system equation
 22
meq/L if 3L free water diuresis
Post-3%N/S natriuresisPost-3%N/S natriuresis
SIADH
Cerebral salt wasting
Case:
SIADH with fixed urine osmolality
600 1L 3% NaCl  11 meq/L ↑
by a closed system
equation
 7 meq/L ↑ if 1L urine Na+K
=250 meq/L
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypervolemicHypervolemic Hyponatremia(1)Hyponatremia(1)
– Without advanced renal insufficiencyWithout advanced renal insufficiency
 Urine NaUrine Na++
< 20 meq/L< 20 meq/L
 Cirrhosis, ascites, CHF, Nephrotic syndromeCirrhosis, ascites, CHF, Nephrotic syndrome
– Advanced acute or chronic renal insufficiencyAdvanced acute or chronic renal insufficiency
 Urine NaUrine Na++
> 20 meq/L> 20 meq/L
 Renal failure (inability to excrete free water)Renal failure (inability to excrete free water)
ELECTROLYTEELECTROLYTE
DISORDERSDISORDERS
 HypervolemicHypervolemic Hyponatremi(2)Hyponatremi(2)
– TreatmentTreatment
 Optimize treatment for underlying disorderOptimize treatment for underlying disorder
 Judicious salt and water restrictionJudicious salt and water restriction
 ++ DiureticsDiuretics
 ++ DialysisDialysis
Hypouricemia in hyponatremiaHypouricemia in hyponatremia
volume mechanism Reference
SIADH N/↑ water↑
Thiazide-induced
hyponatremia
↑/↓ water↑ Fichman et al,
AJM 1971
Polydipsia-induced
hyponatremia
↑ water↑ Hanihara et
al, JCP 58,
256-260, 1997
CSW ↓ ANF
→Proximal tubule
Maesaka et al,
CN 33, 1990
Hyperbilirubinemia
severe
↓ Cholaemia
→ Proximal tubule
Tinatul et al,
JMAT 1970
Trickle-down hyponatremiaTrickle-down hyponatremia
Oh et al, JASN 8: 108A, 1997Oh et al, JASN 8: 108A, 1997
subgroups ↓Solutes ↓ADH Reference
I. Tea/Toast
potomania
Toast: ↓
Protein;
Thiazide for
HTN: ↓Nacl
Tea:
electrolyte-
free water
Boulanger et al,
NDT 14: 2714-
15, 1999
II. Slim
potomania
Low protein
intake/NaCl;
Exercise
↑Water Thaler et al,
AJKD 31:
1028-31, 1998
III. Beer
potomania
↑CHO+fat+a
lcohol;
↓Protein+
NaCl
↑Water Oh et al,
1997
Beer PotomaniaBeer Potomania
 cH2O= Solute excretion/ Uosm﹙1-Uosm/
Posm﹚
 Dependence of water clearance on daily
solute excretion at low urine osmolality(<100)
 Uosm=80mOsm/kg(<100)
solute 300mOsm; cH2O=2.7L;
solute 600, cH2O=5.4;
solute 900, cH2O=8.1L
 Total solute excretion = urea + 2x﹙Na+K﹚
urea= 50x7+100 ~ 150=450( for 70g
protein intake)
Thaler et al, AJKD 1998
Basal water channels(BWC)Basal water channels(BWC)
 Vasopressin-independent water permeability
high in the inner MCD
Lankford et al, AJP 261: 554-566, 1991
 Hereditary DI in rat
Edwards et al, AJP 239: 84-91, 1980
 A different AQP: severe impaired urinary
concentrating ability in transgenic mice
lacking AQP1 water channels
Ma et al, JBC 273:4296-99,1998
 Predominant in the neonatal stage :
physiological DI in water
load≧20ml/Kg→water diuresis
 Chlopropamide↑
BWC>>AQP2BWC>>AQP2
Halperin et al, Clinical Nephrology 56: 339-345, 2001Halperin et al, Clinical Nephrology 56: 339-345, 2001
 In the neonatal stage
 Trickle-down hyponatremia:
Low volume delivery to MCD
low GRF/↑ re-absorption of filtrate in proximal tubule
↑water permeability in cortical distal nephron
low solute excretion rate: Urea+NaCl
low protein diet (low urea)
low NaCl intake ± large non-renal or prior renal NaCl loss
ADH suppression
The Janus effect: 2 faces ofThe Janus effect: 2 faces of
AldosteroneAldosterone
Chronic L-NAME
Sodium Channel: ENaCSodium Channel: ENaC
Modes of ENaC regulationModes of ENaC regulation
Aldosterone/Vasopressin in CDAldosterone/Vasopressin in CD
E Na C Na K ATP ase
Na
K
V2R
Aquaporin
H2O
MR
ATP
c AMP
PKA
Nedd4-2
Aldosterone
Sgk
Nedd4-2: neural precursor cell expressed developmentally down-regulated 4-2
Sgk: serum and glucocorticoid inducible kinase
Aldosterone/Vasopressin/CaSRAldosterone/Vasopressin/CaSR
in CDin CD
E Na C
ROMK
Na K ATP ase
Depolarize
+
Aldosterone
+
Na
K
V2R
Aquaporin
H2O
CaSR
CaSR
Angiotensin II in CNT and CCDAngiotensin II in CNT and CCD
E Na C
ROMK1
Na K ATP ase
Na
K Protein
tyrosine
kinase(c-
Src)
V2R
AT1R
A candidate for an aldosterone-independent mediator of K preservation
during volume depletion
Clinical correlation of ENaCClinical correlation of ENaC
Vivek Bhalla et al: JASN 19: 1845-54,2008
Processing of natriuretic peptideProcessing of natriuretic peptide
ConvertaseSignal peptidase
Corin: new insights into ANPCorin: new insights into ANP
Corin: a transmembrane serine protease
identified in the heart
Convert pro-ANP to active ANP
Lack of corin →
Salt sensitive HTN in mice
Single nucleotide polymorphism→
African Americans with HTN and cardiac
hypertrophy Q Wu et al: KI 75: 142-146, 2009
Mutations of renal Na channelsMutations of renal Na channels
 Liddle syndrome: β and γ subunits of amiloride-sensitive
ENaC
 Gordon syndrome: WNK1 and WNK4 kinases
 Glucocorticoid remediable aldosteronism: aldosterone
synthase/11 β hydroxylase
 Adrenal hyperplasia: 11α hydroxylase/β hydroxylase
 Apparent mineralocorticoid excess: mineralocorticoid
receptor, 11 βhydroxystreoid dehydrogenase
 Progersterone induced hypertension: mineralocorticoid
receptor
 Psuedo-hypoaldosteronism (PHA)
PseudoHypoAldosteronism: PHAPseudoHypoAldosteronism: PHA
Bonny et al, JASN 13: 2399-2414, 2002Bonny et al, JASN 13: 2399-2414, 2002
Clinical Gene Defects
Type I: AR
AD
Renal: salt wasting/hypo-Na
Hyper-K
Metabolic acidosis
PAC↑/PRA↑
Extra-renal: chest, GI, skin
Renal : spontaneous remission
ENaC
Mineracorticoid receptor
Type II: AD
( Gordon syndrome )
Renal: HTN, salt sensitive
Hyper-K
HCMA
normal PAC; PRA↓
A: 1q31-q42
B: WNK4
C: WNK1
Type III:
Acquired
(obstructive
nephropathy; UTI;
lead; amyloidosis)
GFR↓; Excessive salt loss
Hyper-K
HCMA
PAC↑/PRA↑
Transient PHA
Salt transport in DCTSalt transport in DCT
TSC
Na
2Cl
V2R
Inactive
TSC dimer TSC
monomer
AT1R
MR
SPAK
PHA-2: WNK1&4/SPAK/TSCPHA-2: WNK1&4/SPAK/TSC
(gain)(gain)
TSC
Na
2Cl
Inactive
TSC dimer TSC
monomer
SPAK
4
1
Sei Sasaki: Tokyo Medical and Dental University
Chloride channel: CLCChloride channel: CLC
hCLC-Ka
(rCLC-K1)
hCLC-Kb
(rCLC-K2)
CLC-5
Location TALH,
basolateral
TALH, DCT,
αIC basolateral
PCT, αIC
intracelluar
shunt by H
ATPase
Disease NDI, DDAVP-
insensitive
(Clcnk1)
Tyep III Bartter
syndrome
(CLCNKB)
Mixed Bartter-
Gitelman
(CLCNKB)
XLR
nephrolithiasis
(Dent’s: CLC-5)
↓Receptor-
mediated
endocytosis
Variants of Bartter’s syndromeVariants of Bartter’s syndrome
Israel Zelikovic, NDT 18: 1696-1700, 2003Israel Zelikovic, NDT 18: 1696-1700, 2003
Defective
transporter/protein
Clinical Locus
Type I NKCC2 (TAL) Antenatal 15q
Type II ROMK (TAL/CD) Antenatal 11q
Type III ClC-Kb (TAL,DCT) Classic 1p36
Type IV Barttin (β of CIC-
Ka/CIC-Kb)
BSND
(Deafness)
1p31
AD
Hypercalciuria
CaSR
(PT/TAL/DCT/CD)
Hypocalcemia 3q
Bartter’s syndrome in THALBartter’s syndrome in THAL
NKCC
ROMK
Na K ATP ase
Ca, Mg pH
Na/K
K
2Cl
CaSR
Negative
Positive
ClC-Kb
2
1
3
Bartter with Sensori-NeuralBartter with Sensori-Neural
DeafnessDeafness
BSND
Barttin forms heterodimers
with ClC-Ka in thin ALH
with ClC-Kb in thick
ALH→ NDI
with ClC-K in marginal cells of stria
vascularis (inner ear) & vestibular dark cells
Gitelman’s / Bartter’s syndromeGitelman’s / Bartter’s syndrome
Gitelman’s Bartter’s
Molecular level ↓TSC in DCT ↓NKCC, ROMK, or
Cl
Age at onset Teenage Children
Clinical Tetany Failure to thrive
Mimicked by Thiazides Loop diuretics
Plasma Mg ↓ ↓
D.D. Hypocalciuria Hypercalciuria
Uosm ↓
Thiazide-induced hyponatremiaThiazide-induced hyponatremia
Renal salt wasting: via TSC in DCT
Water retention:
hypovolemia-induced ADH release
direct effect of ↑distal water reabsorption
( via PGE2↓; indomethacin↑)
Magaldi et al, NDT 15: 1903-5, 2000
↑thirst and water intake
No calcium wasting
Salt transport in DCTSalt transport in DCT
TSC
Na
2Cl
V2R
Inactive
TSC dimer TSC
monomer
AT1R
MR
SPAK
Vasopressin/CaSR in DCTVasopressin/CaSR in DCT
TSC
TRPV5
Na K ATP ase
pH pH
Na
Ca
2Cl
CaSR
Positive
PositiveCaSR
CaATPase
NCX
V2R
Kinase
SPAK
Salt-losing nephropathySalt-losing nephropathy
Salt-losing nephropathy with
inappropriate secretion of ANP( 10 ~
47fmol/ml): no cardiac or cerebral
abnormality pseudo-bartter
syndrome: concentaring power highly-conserved;
normokalemic metabolic alkalosis; no response
to indomethacin therapy
 Granulomatous interstitial nephritis&uveitis:
non-caseating granuloma
6-M steroid therapy
Primary renal candidiasis:
caseating renal granuloma→medullary destruction
Milk alkali syndromeMilk alkali syndrome
↑Free P-Ca++ /Mg++
CaCO3 in duodenum + ferment H+
→ Free Ca++ in lumen;
if low HPO4 in GI (poor intake)
→ Free P-Ca++ ↑ via para-
cellular route
Hypercalcemia GFR↓
Anorexia nervosa + AntacidsAnorexia nervosa + Antacids
Mitchell Lewis HalperinMitchell Lewis Halperin
P-Na=118mM ; U-Na 44mM
pH=7.2; P-HCO3=9
P-K=2.0mM; U-K=17mM
K deficit >120
P-Ca 2.56mM; P-alb 2.7g/dl
UV>6L; Uosm=150
P-Mg 1.5mM
Shaded areas refer to changes in total body sodium because of
differences in intake and excretion
‘skin Na+
storage’
Macrophages act as local osmo-sensors
Weekly (circaseptan) patterns in sodium excretion:
inversely related to aldosterone and directly to cortisol.
TBNa : monthly (infradian) rhythms independent of
extracellular water, body weight, or blood pressure
nstead exhibited far longer ( monthly) infradian rhythms independent of ext
instead exhibited far longer ( monthly) infradian rhythms independent of ex
23
Na-magnetic resonance imaging (MRI) can measure sodium in the
skin and muscle at the calf: despite remarkable reduction in tissue Na+
content, no change in body weight was observed
A new perspective on hyponatremia

Weitere ähnliche Inhalte

Was ist angesagt?

Hyponatremia gulidelines
Hyponatremia  gulidelinesHyponatremia  gulidelines
Hyponatremia gulidelines
Viquas Saim
 
hyponatremia -my prensentation
hyponatremia -my prensentationhyponatremia -my prensentation
hyponatremia -my prensentation
Sudhir K. Yadav
 

Was ist angesagt? (20)

Hypernatremia - Stepwise Practical Approach - Dr. Gawad
Hypernatremia - Stepwise Practical Approach - Dr. GawadHypernatremia - Stepwise Practical Approach - Dr. Gawad
Hypernatremia - Stepwise Practical Approach - Dr. Gawad
 
Approach to hyponatremia
Approach to hyponatremiaApproach to hyponatremia
Approach to hyponatremia
 
Hyponatremia 2015 final
Hyponatremia 2015 finalHyponatremia 2015 final
Hyponatremia 2015 final
 
Hypernatremia (Practical Approach) - Dr. Gawad
Hypernatremia (Practical Approach) - Dr. GawadHypernatremia (Practical Approach) - Dr. Gawad
Hypernatremia (Practical Approach) - Dr. Gawad
 
Hyponatremia gulidelines
Hyponatremia  gulidelinesHyponatremia  gulidelines
Hyponatremia gulidelines
 
Hyponatremia- A low sodium concentration in the blood
Hyponatremia- A low sodium concentration in the bloodHyponatremia- A low sodium concentration in the blood
Hyponatremia- A low sodium concentration in the blood
 
Hyertension in patients on regular hemodialysis
Hyertension in patients on regular hemodialysisHyertension in patients on regular hemodialysis
Hyertension in patients on regular hemodialysis
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. GawadElectrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
Electrolytes & Acid-Base Disturbance Workshop - Dr. Gawad
 
Approach to hyponatremia
Approach to hyponatremiaApproach to hyponatremia
Approach to hyponatremia
 
Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...
Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...
Non EPO Management of Renal Anemia - Different Lines & Available Evidence - D...
 
Ckd mbd
Ckd mbdCkd mbd
Ckd mbd
 
Hyponatremia (Practical Approach) - Dr. Gawad
Hyponatremia (Practical Approach) - Dr. GawadHyponatremia (Practical Approach) - Dr. Gawad
Hyponatremia (Practical Approach) - Dr. Gawad
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
Hyperkalemia (Practical Approach) - Dr. Gawad
Hyperkalemia (Practical Approach) - Dr. GawadHyperkalemia (Practical Approach) - Dr. Gawad
Hyperkalemia (Practical Approach) - Dr. Gawad
 
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. GawadIs It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
Is It Diabetic Nephropathy? (When to Biopsy?) - Dr. Gawad
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
Diuretics in CKD
Diuretics in CKDDiuretics in CKD
Diuretics in CKD
 
How to retard the progression of ckd dr Tareq tantawy
How to retard the progression of ckd dr Tareq tantawyHow to retard the progression of ckd dr Tareq tantawy
How to retard the progression of ckd dr Tareq tantawy
 
hyponatremia -my prensentation
hyponatremia -my prensentationhyponatremia -my prensentation
hyponatremia -my prensentation
 

Ähnlich wie A new perspective on hyponatremia

A New Perspective on Hypernatremia
A New Perspective on HypernatremiaA New Perspective on Hypernatremia
A New Perspective on Hypernatremia
Steve Chen
 
Electrolyte disorder
Electrolyte disorderElectrolyte disorder
Electrolyte disorder
Ashiqur Papel
 
Electrolyte imbalance
Electrolyte imbalanceElectrolyte imbalance
Electrolyte imbalance
VIJAI KUMAR
 
Neurology of electrolyte imbalance
Neurology of electrolyte imbalanceNeurology of electrolyte imbalance
Neurology of electrolyte imbalance
NeurologyKota
 

Ähnlich wie A new perspective on hyponatremia (20)

TAEM10:Electrolyte emergency
TAEM10:Electrolyte emergencyTAEM10:Electrolyte emergency
TAEM10:Electrolyte emergency
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
Electrolyte Imbalance
Electrolyte ImbalanceElectrolyte Imbalance
Electrolyte Imbalance
 
A New Perspective on Hypernatremia
A New Perspective on HypernatremiaA New Perspective on Hypernatremia
A New Perspective on Hypernatremia
 
Hyopna 9090909
Hyopna     9090909Hyopna     9090909
Hyopna 9090909
 
Hyopna 9090909
Hyopna     9090909Hyopna     9090909
Hyopna 9090909
 
Hyopna 9090909
Hyopna     9090909Hyopna     9090909
Hyopna 9090909
 
Hyopna 9090909
Hyopna     9090909Hyopna     9090909
Hyopna 9090909
 
Sodium Imbalances in NEURO ICU.pptx
Sodium Imbalances in NEURO ICU.pptxSodium Imbalances in NEURO ICU.pptx
Sodium Imbalances in NEURO ICU.pptx
 
Dyselectrolytemia by Dr Sheikh Tufail
Dyselectrolytemia by Dr Sheikh TufailDyselectrolytemia by Dr Sheikh Tufail
Dyselectrolytemia by Dr Sheikh Tufail
 
Electrolyte disorder
Electrolyte disorderElectrolyte disorder
Electrolyte disorder
 
METABOLIC EMERGENCIES.pptx
METABOLIC EMERGENCIES.pptxMETABOLIC EMERGENCIES.pptx
METABOLIC EMERGENCIES.pptx
 
Electrolyte imbalance
Electrolyte imbalanceElectrolyte imbalance
Electrolyte imbalance
 
ELECTROLYTE.pptx
ELECTROLYTE.pptxELECTROLYTE.pptx
ELECTROLYTE.pptx
 
Dialysis emergencies
Dialysis emergencies Dialysis emergencies
Dialysis emergencies
 
Hyponatremia new
Hyponatremia newHyponatremia new
Hyponatremia new
 
Neurology of electrolyte imbalance
Neurology of electrolyte imbalanceNeurology of electrolyte imbalance
Neurology of electrolyte imbalance
 
Dyselectrolytemias in ic us detailed
Dyselectrolytemias in ic us  detailedDyselectrolytemias in ic us  detailed
Dyselectrolytemias in ic us detailed
 
Dyselectrolytemias in ic us detailed
Dyselectrolytemias in ic us  detailedDyselectrolytemias in ic us  detailed
Dyselectrolytemias in ic us detailed
 
Hyponatremia 040113.ppt
Hyponatremia 040113.pptHyponatremia 040113.ppt
Hyponatremia 040113.ppt
 

Mehr von Steve Chen (14)

A new perspective on hypermagnesemia
A new perspective on hypermagnesemiaA new perspective on hypermagnesemia
A new perspective on hypermagnesemia
 
A new perspective on hypomagnesemia
A new perspective on hypomagnesemiaA new perspective on hypomagnesemia
A new perspective on hypomagnesemia
 
A new perspective on metabolic alkalosis
A new perspective on metabolic alkalosisA new perspective on metabolic alkalosis
A new perspective on metabolic alkalosis
 
A new perspective on metabolic acidosis
A new perspective on metabolic acidosisA new perspective on metabolic acidosis
A new perspective on metabolic acidosis
 
A new perspective on hypokalemia
A new perspective on hypokalemiaA new perspective on hypokalemia
A new perspective on hypokalemia
 
A New Perspective on Hyperkalemia
A New Perspective on HyperkalemiaA New Perspective on Hyperkalemia
A New Perspective on Hyperkalemia
 
A New Perspective on Hyperphosphatemia
A New Perspective on HyperphosphatemiaA New Perspective on Hyperphosphatemia
A New Perspective on Hyperphosphatemia
 
A New Perspective on Hypophosphatemia
A New Perspective on HypophosphatemiaA New Perspective on Hypophosphatemia
A New Perspective on Hypophosphatemia
 
A New Perspective on Hypocalcemia
A New Perspective on HypocalcemiaA New Perspective on Hypocalcemia
A New Perspective on Hypocalcemia
 
A New Perspective on CKD
A New Perspective on CKDA New Perspective on CKD
A New Perspective on CKD
 
A New Perspective on AKI
A New Perspective on AKIA New Perspective on AKI
A New Perspective on AKI
 
A New Perspective on Vascular Access
A New Perspective on Vascular AccessA New Perspective on Vascular Access
A New Perspective on Vascular Access
 
Metrics for hemodialysis quality care
Metrics for hemodialysis quality careMetrics for hemodialysis quality care
Metrics for hemodialysis quality care
 
A New Landscape on Hypercalcemia
A New Landscape on HypercalcemiaA New Landscape on Hypercalcemia
A New Landscape on Hypercalcemia
 

Kürzlich hochgeladen

Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
ZurliaSoop
 

Kürzlich hochgeladen (20)

Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Tatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf artsTatlong Kwento ni Lola basyang-1.pdf arts
Tatlong Kwento ni Lola basyang-1.pdf arts
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.ICT role in 21st century education and it's challenges.
ICT role in 21st century education and it's challenges.
 
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptxCOMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
COMMUNICATING NEGATIVE NEWS - APPROACHES .pptx
 
Plant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptxPlant propagation: Sexual and Asexual propapagation.pptx
Plant propagation: Sexual and Asexual propapagation.pptx
 
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
Jual Obat Aborsi Hongkong ( Asli No.1 ) 085657271886 Obat Penggugur Kandungan...
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
latest AZ-104 Exam Questions and Answers
latest AZ-104 Exam Questions and Answerslatest AZ-104 Exam Questions and Answers
latest AZ-104 Exam Questions and Answers
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 

A new perspective on hyponatremia

  • 1. A New Perspective onA New Perspective on HyponatremiaHyponatremia by Steve Chenby Steve Chen Director of Nephrology, Shin-Chu Branch of Taipei Veterans General Hospital
  • 4.
  • 5. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  Serum NaSerum Na++ < 135 meq/L< 135 meq/L – Symptoms due to brain edema:Symptoms due to brain edema: headache & vomiting ifheadache & vomiting if NaNa++ < 120< 120 meq/Lmeq/L – CNS symptoms:CNS symptoms: convulsions ifconvulsions if NaNa++ < 113 meq/L< 113 meq/L – CV symptoms:CV symptoms: CV collapse ifCV collapse if Na < 100 meq/LNa < 100 meq/L Hyponatremia
  • 6. HyponatremiaHyponatremia Causes an osmotic fluid shift from plasma into brain cells
  • 7. Hyponatremic encephalopathyHyponatremic encephalopathy  Hospital acquired: SIADH Post-operative state: 3-4 L hypotonic fluid in 2 days in female  fatal Encephalitis in children: fatal  Risk factors: Children : non-osmotic stimuli of ADH ↑brain/intracranial volume Female: sex steroid inhibit brain adaptation Hypoxemia
  • 8. Hyponatremic encephalopathyHyponatremic encephalopathy Outpatient : Medications Psychogenic polydipsia Water intoxification in infants Marathon runners Hip fracture S/P colonoscopy : ADH↑from bowel manipulation + polyethelene glycol for bowel preparation Recreational drug:
  • 9. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  Pathophysiology: CNSPathophysiology: CNS – Water shifts into brain cellsWater shifts into brain cells – ApathyApathy –– Altered ConsciousnessAltered Consciousness – AgitationAgitation –– ConvulsionsConvulsions – HeadacheHeadache –– ComaComa – Risk of brain damage > during treatmentRisk of brain damage > during treatment – Cerebral demyelination syndrome(CDS)Cerebral demyelination syndrome(CDS) Hyponatremia
  • 10. Cerebral Demylination SyndromeCerebral Demylination Syndrome CDSCDS risk factorsrisk factors  Development of Hypernatremia  ↑S-Na > 25 meq /L in 48Hrs  Hypoxemia  Hypokalemia  Mal-nutrition  Severe liver disease  Alcoholism  Severe burns  Cancer  U osm ≤ 150 Kg/L
  • 11.
  • 12. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  Serum OsmolalitySerum Osmolality – Number of osmoles (osmotically activeNumber of osmoles (osmotically active particles) in the serumparticles) in the serum – Normal rangeNormal range  275 to 295 mosm/L275 to 295 mosm/L Fluid Balance 2[Serum Na+ ] + ------------ + ------------ Glucose BUN 18 2.8
  • 13. ELECTROLYTE DISORDERSELECTROLYTE DISORDERS HyponatremiaHyponatremia Flow of D.D.Flow of D.D. Plasma Osmolality Normal (275-295) Isotonic hyponatremia Low (< 275) Hypotonic hyponatremia High (> 295) Hypertonic hyponatremia Hypovolemic Hypervolemic Euvolemic
  • 14. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypertonicHypertonic HyponatremiaHyponatremia (P(Posmosm > 295)> 295) – Large quantities of solute in ECFLarge quantities of solute in ECF – Water moves from ICF ECFWater moves from ICF ECF – HyperglycemiaHyperglycemia most common causemost common cause  Each 100 mg/dl plasma glucose will serumEach 100 mg/dl plasma glucose will serum NaNa++ by 1.6 meq/Lby 1.6 meq/L – TreatmentTreatment  Volume replacementVolume replacement Hyponatremia, hypertonic
  • 15. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  IsotonicIsotonic HyponatremiaHyponatremia (P(Posmosm 275 - 295)275 - 295) – ““PseudohyponatremiaPseudohyponatremia”” – Artifact in serum NaArtifact in serum Na++ measurementmeasurement  2° High levels of plasma proteins and lipids2° High levels of plasma proteins and lipids – Etiology:Etiology:  HyperlipidemiaHyperlipidemia  HyperproteinemiaHyperproteinemia Hyponatremia, isotonic
  • 16. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypotonicHypotonic HyponatremiaHyponatremia (P(Posmosm < 275)< 275) Plasma Osmolality Normal (275-295) Isotonic hyponatremia Low (< 275) Hypotonic hyponatremia High (> 295) Hypertonic hyponatremia Hypovolemic Hypervolemic Euvolemic Hyponatremia, hypotonic
  • 17.
  • 18. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypovolemicHypovolemic HyponatremiaHyponatremia – RenalRenal NaNa++ lossloss  Urine NaUrine Na++ > 20 meq/L> 20 meq/L  Etiology:Etiology: – Diuretic useDiuretic use – Salt-wasting nephropathy (renal tubular acidosis, chronicSalt-wasting nephropathy (renal tubular acidosis, chronic renal failure, interstitial nephritis)renal failure, interstitial nephritis) – Osmotic diuresis (glucose, urea, mannitol,Osmotic diuresis (glucose, urea, mannitol, hyperproteinemiahyperproteinemia – Mineralocorticoid (aldosterone) deficiencyMineralocorticoid (aldosterone) deficiency
  • 19. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypovolemicHypovolemic HyponatremiaHyponatremia – ExtrarenalExtrarenal NaNa++ lossloss  Urine NaUrine Na++ < 20 meq/L< 20 meq/L  Etiology:Etiology: – Volume replacement with hypotonic fluidsVolume replacement with hypotonic fluids – GI loss (vomiting, diarrhea, fistula, tube suction)GI loss (vomiting, diarrhea, fistula, tube suction) – Third-space loss (burns, hemorrhagic pancreatitis,Third-space loss (burns, hemorrhagic pancreatitis, peritonitis)peritonitis) – Sweating (cystic fibrosis)Sweating (cystic fibrosis)
  • 20. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypovolemicHypovolemic HyponatremiaHyponatremia – TreatmentTreatment  Re-expansion of ECF withRe-expansion of ECF with isotonic salineisotonic saline  Correction of underlying disorderCorrection of underlying disorder
  • 21. To calculate Na deficitTo calculate Na deficit Sodium deficit = total body water X (desired Na - present Na) TBW = body wt x 0.6 males 0.5 females
  • 22. Sodium DeficitSodium Deficit  Na deficit= Vd of plasma Na x Na deficit per liter﹝ ﹞  Vd of plasma Na = TBWa = 0.5 x LBW if﹝ ﹞ female =0.6 x LBW if man  60Kg woman, Thiazide 5 days, acute confusion, plasma Na = 108meq/L. If Na =120 is safe,﹝ ﹞ ﹝ ﹞ sodium deficit= 0.5x 60x﹙120-108 =360﹚  Urine Na> 40meq/L indicates Normovolemia restored  NS supplied for fear of postsupply overdiuresis
  • 23. Post-N/S diuresis: turn off ADHPost-N/S diuresis: turn off ADH U osm <100 mOsm Initial rate before P-Na targeted: ongoing free water loss = UV x [ 1-( UNa+UK / PNa+PK ) ] Later rate after P-Na targeted: free water loss = UV x [ 1-( UNa+UK-oral Na+K-IV
  • 24.
  • 25. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  EuvolemicEuvolemic Hyponatremia(1)Hyponatremia(1) – SIADHSIADH  Hypotonic hyponatremiaHypotonic hyponatremia  Inappropriately elevated urine osmolality (usually > 200Inappropriately elevated urine osmolality (usually > 200 mosm/kg)mosm/kg)  Elevated urine NaElevated urine Na++ (> 20 meq/L)(> 20 meq/L)  Clinical euvolemiaClinical euvolemia  Normal adrenal, renal, cardiac, hepatic, and thyroid functionNormal adrenal, renal, cardiac, hepatic, and thyroid function
  • 26. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  EuvolemicEuvolemic Hyponatremia(2)Hyponatremia(2) – Etiology:Etiology:  HypothyroidismHypothyroidism  Pain, stress, nausea, psychosis (stimulates ADH)Pain, stress, nausea, psychosis (stimulates ADH)  Drugs: ADH, nicotine, sulfonylureas, morphine,Drugs: ADH, nicotine, sulfonylureas, morphine, barbs, NSAIDS, APAP, Carbamazepine,barbs, NSAIDS, APAP, Carbamazepine, Phenothiazines, TCAs, Colchicine, Clofibrate,Phenothiazines, TCAs, Colchicine, Clofibrate, Cyclophosphamide, Isoproterenol, Tolbutamide,Cyclophosphamide, Isoproterenol, Tolbutamide, MAOIsMAOIs
  • 27. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  EuvolemicEuvolemic Hyponatremia(3)Hyponatremia(3) – Etiology:Etiology:  Water intoxication (psychogenic polydipsia)Water intoxication (psychogenic polydipsia)  Glucocorticoid deficiencyGlucocorticoid deficiency  Positive pressure ventilationPositive pressure ventilation  PorphyriaPorphyria  Essential (reset osmostat orEssential (reset osmostat or sick cell syndromesick cell syndrome))
  • 28. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  Treatment of Severe Hyponatremia(4)Treatment of Severe Hyponatremia(4) – Indications:Indications:  Serum NaSerum Na++ < 120 meq/L< 120 meq/L  Rapid development ( NaRapid development ( Na++ > 0.5 meq/L/hr)> 0.5 meq/L/hr)  Patient in extremis (coma, seizures)Patient in extremis (coma, seizures) – 3% Saline Solution (513 meq/L) @3% Saline Solution (513 meq/L) @ 25 - 10025 - 100 ml/hrml/hr  NaNa++ should not exceed 0.5 – 1.0 meq/L/hrshould not exceed 0.5 – 1.0 meq/L/hr
  • 29. Time Classification of SIADH-Time Classification of SIADH- HyponatremiaHyponatremia Duration Clinical setting Risk Therapy Acute <48Hr Post- operative Brain cell swelling ↑﹝Na by up﹞ to 5meq/L/H Chronic Unknown Or > 48Hr Many Cerebral demyelination syndrome ↑﹝Na﹞ <0.33meq/L/ H
  • 30. Therapy for SIADHTherapy for SIADH  Aggressive Tx only for Pts with coma/seizure: ↑ Na up to 5meq/L to control CNS S/S; then﹝ ﹞ ↑ Na 8meq/L/D﹝ ﹞≦  Slow correction when brain cell size normal ↑ Na 8meq/L/D to prevent CDS﹝ ﹞≦ 3% NaCl 1cc/Kg/Hr= ↑ Na 1meq/L/Hr﹝ ﹞  Even slower correction if manutrition or hypercatabolic state(poor availability of K or organic osmoles
  • 31. SIADH with chronic hyponatremiaSIADH with chronic hyponatremia A 50Kg,SIADH due to tumor, plasma Na 120meq/L, asymptomatic﹝ ﹞ TBW=30L; ICF 20L Total ICF osmoles normally=20x2x140=5600 If ICF osmoles unchanged, ICF=5600/2x120=23.2L Time(hr)=140-120/0.5=40Hr  Therapeutic goal: To lose 3L of EFW within 40Hr
  • 32. Treatment guidelinesTreatment guidelines Administration of oral or IV Na+ (3%) Supplements Encourage foods high in Na+ Fluid restriction Monitor Neurological Status Normovolemic hyponatremia:V2 antagonist – Vaprisol (conivaptan) – IV infusion – Samsca (tolvaptan) - PO
  • 33.
  • 34. Renal water channels: AQPRenal water channels: AQP  Aquaporins: AQP 0 ~ 12  AQP 0: Cataract  AQP 1 in proximal & thin descending LOH: re-absorption of most filtered fluid= partial NDI  AQP 2 in apical of collecting duct: urine concentration= NDI  AQP 3 & 4 in baso-lateral of collecting duct:  AQP 5: SS  AQP 7 in apical of S3 proximal: 10% as water route; glycerol re-absorption  AQP 11 in intracellular vesicles: PCKD Sei Sasaki: Tokyo Medical and Dental
  • 35. AQP 2 binding protein complexAQP 2 binding protein complex Trafficking of AQP2 Mis-routing to baso-lateral membrane instead of apical SPA-1: a GTP-ase activating protein for Rap1 Cytoskeleton protein actin Sei Sasaki: Tokyo Medical and Dental University
  • 36. Urinary concentration modulationUrinary concentration modulation ↑ c AMP AQP2 trafficking and expression
  • 37. Post-3%N/S free water diuresisPost-3%N/S free water diuresis  Psychogenic polydipsia  DC of DDAVP  Water intoxification in infants  Hypotonic fluid plus DDAVP for overcorrection of hyponatremia  Case: 70Kg, TBW 35, S-Na 110meq/L 1L 3% NaCl  11.2 meq/L↑ by closed system equation  22 meq/L if 3L free water diuresis
  • 38. Post-3%N/S natriuresisPost-3%N/S natriuresis SIADH Cerebral salt wasting Case: SIADH with fixed urine osmolality 600 1L 3% NaCl  11 meq/L ↑ by a closed system equation  7 meq/L ↑ if 1L urine Na+K =250 meq/L
  • 39.
  • 40. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypervolemicHypervolemic Hyponatremia(1)Hyponatremia(1) – Without advanced renal insufficiencyWithout advanced renal insufficiency  Urine NaUrine Na++ < 20 meq/L< 20 meq/L  Cirrhosis, ascites, CHF, Nephrotic syndromeCirrhosis, ascites, CHF, Nephrotic syndrome – Advanced acute or chronic renal insufficiencyAdvanced acute or chronic renal insufficiency  Urine NaUrine Na++ > 20 meq/L> 20 meq/L  Renal failure (inability to excrete free water)Renal failure (inability to excrete free water)
  • 41. ELECTROLYTEELECTROLYTE DISORDERSDISORDERS  HypervolemicHypervolemic Hyponatremi(2)Hyponatremi(2) – TreatmentTreatment  Optimize treatment for underlying disorderOptimize treatment for underlying disorder  Judicious salt and water restrictionJudicious salt and water restriction  ++ DiureticsDiuretics  ++ DialysisDialysis
  • 42.
  • 43. Hypouricemia in hyponatremiaHypouricemia in hyponatremia volume mechanism Reference SIADH N/↑ water↑ Thiazide-induced hyponatremia ↑/↓ water↑ Fichman et al, AJM 1971 Polydipsia-induced hyponatremia ↑ water↑ Hanihara et al, JCP 58, 256-260, 1997 CSW ↓ ANF →Proximal tubule Maesaka et al, CN 33, 1990 Hyperbilirubinemia severe ↓ Cholaemia → Proximal tubule Tinatul et al, JMAT 1970
  • 44. Trickle-down hyponatremiaTrickle-down hyponatremia Oh et al, JASN 8: 108A, 1997Oh et al, JASN 8: 108A, 1997 subgroups ↓Solutes ↓ADH Reference I. Tea/Toast potomania Toast: ↓ Protein; Thiazide for HTN: ↓Nacl Tea: electrolyte- free water Boulanger et al, NDT 14: 2714- 15, 1999 II. Slim potomania Low protein intake/NaCl; Exercise ↑Water Thaler et al, AJKD 31: 1028-31, 1998 III. Beer potomania ↑CHO+fat+a lcohol; ↓Protein+ NaCl ↑Water Oh et al, 1997
  • 45. Beer PotomaniaBeer Potomania  cH2O= Solute excretion/ Uosm﹙1-Uosm/ Posm﹚  Dependence of water clearance on daily solute excretion at low urine osmolality(<100)  Uosm=80mOsm/kg(<100) solute 300mOsm; cH2O=2.7L; solute 600, cH2O=5.4; solute 900, cH2O=8.1L  Total solute excretion = urea + 2x﹙Na+K﹚ urea= 50x7+100 ~ 150=450( for 70g protein intake) Thaler et al, AJKD 1998
  • 46. Basal water channels(BWC)Basal water channels(BWC)  Vasopressin-independent water permeability high in the inner MCD Lankford et al, AJP 261: 554-566, 1991  Hereditary DI in rat Edwards et al, AJP 239: 84-91, 1980  A different AQP: severe impaired urinary concentrating ability in transgenic mice lacking AQP1 water channels Ma et al, JBC 273:4296-99,1998  Predominant in the neonatal stage : physiological DI in water load≧20ml/Kg→water diuresis  Chlopropamide↑
  • 47. BWC>>AQP2BWC>>AQP2 Halperin et al, Clinical Nephrology 56: 339-345, 2001Halperin et al, Clinical Nephrology 56: 339-345, 2001  In the neonatal stage  Trickle-down hyponatremia: Low volume delivery to MCD low GRF/↑ re-absorption of filtrate in proximal tubule ↑water permeability in cortical distal nephron low solute excretion rate: Urea+NaCl low protein diet (low urea) low NaCl intake ± large non-renal or prior renal NaCl loss ADH suppression
  • 48.
  • 49. The Janus effect: 2 faces ofThe Janus effect: 2 faces of AldosteroneAldosterone Chronic L-NAME
  • 50. Sodium Channel: ENaCSodium Channel: ENaC Modes of ENaC regulationModes of ENaC regulation
  • 51. Aldosterone/Vasopressin in CDAldosterone/Vasopressin in CD E Na C Na K ATP ase Na K V2R Aquaporin H2O MR ATP c AMP PKA Nedd4-2 Aldosterone Sgk Nedd4-2: neural precursor cell expressed developmentally down-regulated 4-2 Sgk: serum and glucocorticoid inducible kinase
  • 52. Aldosterone/Vasopressin/CaSRAldosterone/Vasopressin/CaSR in CDin CD E Na C ROMK Na K ATP ase Depolarize + Aldosterone + Na K V2R Aquaporin H2O CaSR CaSR
  • 53. Angiotensin II in CNT and CCDAngiotensin II in CNT and CCD E Na C ROMK1 Na K ATP ase Na K Protein tyrosine kinase(c- Src) V2R AT1R A candidate for an aldosterone-independent mediator of K preservation during volume depletion
  • 54. Clinical correlation of ENaCClinical correlation of ENaC Vivek Bhalla et al: JASN 19: 1845-54,2008
  • 55. Processing of natriuretic peptideProcessing of natriuretic peptide ConvertaseSignal peptidase
  • 56. Corin: new insights into ANPCorin: new insights into ANP Corin: a transmembrane serine protease identified in the heart Convert pro-ANP to active ANP Lack of corin → Salt sensitive HTN in mice Single nucleotide polymorphism→ African Americans with HTN and cardiac hypertrophy Q Wu et al: KI 75: 142-146, 2009
  • 57. Mutations of renal Na channelsMutations of renal Na channels  Liddle syndrome: β and γ subunits of amiloride-sensitive ENaC  Gordon syndrome: WNK1 and WNK4 kinases  Glucocorticoid remediable aldosteronism: aldosterone synthase/11 β hydroxylase  Adrenal hyperplasia: 11α hydroxylase/β hydroxylase  Apparent mineralocorticoid excess: mineralocorticoid receptor, 11 βhydroxystreoid dehydrogenase  Progersterone induced hypertension: mineralocorticoid receptor  Psuedo-hypoaldosteronism (PHA)
  • 58. PseudoHypoAldosteronism: PHAPseudoHypoAldosteronism: PHA Bonny et al, JASN 13: 2399-2414, 2002Bonny et al, JASN 13: 2399-2414, 2002 Clinical Gene Defects Type I: AR AD Renal: salt wasting/hypo-Na Hyper-K Metabolic acidosis PAC↑/PRA↑ Extra-renal: chest, GI, skin Renal : spontaneous remission ENaC Mineracorticoid receptor Type II: AD ( Gordon syndrome ) Renal: HTN, salt sensitive Hyper-K HCMA normal PAC; PRA↓ A: 1q31-q42 B: WNK4 C: WNK1 Type III: Acquired (obstructive nephropathy; UTI; lead; amyloidosis) GFR↓; Excessive salt loss Hyper-K HCMA PAC↑/PRA↑ Transient PHA
  • 59. Salt transport in DCTSalt transport in DCT TSC Na 2Cl V2R Inactive TSC dimer TSC monomer AT1R MR SPAK
  • 60. PHA-2: WNK1&4/SPAK/TSCPHA-2: WNK1&4/SPAK/TSC (gain)(gain) TSC Na 2Cl Inactive TSC dimer TSC monomer SPAK 4 1 Sei Sasaki: Tokyo Medical and Dental University
  • 61. Chloride channel: CLCChloride channel: CLC hCLC-Ka (rCLC-K1) hCLC-Kb (rCLC-K2) CLC-5 Location TALH, basolateral TALH, DCT, αIC basolateral PCT, αIC intracelluar shunt by H ATPase Disease NDI, DDAVP- insensitive (Clcnk1) Tyep III Bartter syndrome (CLCNKB) Mixed Bartter- Gitelman (CLCNKB) XLR nephrolithiasis (Dent’s: CLC-5) ↓Receptor- mediated endocytosis
  • 62. Variants of Bartter’s syndromeVariants of Bartter’s syndrome Israel Zelikovic, NDT 18: 1696-1700, 2003Israel Zelikovic, NDT 18: 1696-1700, 2003 Defective transporter/protein Clinical Locus Type I NKCC2 (TAL) Antenatal 15q Type II ROMK (TAL/CD) Antenatal 11q Type III ClC-Kb (TAL,DCT) Classic 1p36 Type IV Barttin (β of CIC- Ka/CIC-Kb) BSND (Deafness) 1p31 AD Hypercalciuria CaSR (PT/TAL/DCT/CD) Hypocalcemia 3q
  • 63. Bartter’s syndrome in THALBartter’s syndrome in THAL NKCC ROMK Na K ATP ase Ca, Mg pH Na/K K 2Cl CaSR Negative Positive ClC-Kb 2 1 3
  • 64. Bartter with Sensori-NeuralBartter with Sensori-Neural DeafnessDeafness BSND Barttin forms heterodimers with ClC-Ka in thin ALH with ClC-Kb in thick ALH→ NDI with ClC-K in marginal cells of stria vascularis (inner ear) & vestibular dark cells
  • 65.
  • 66. Gitelman’s / Bartter’s syndromeGitelman’s / Bartter’s syndrome Gitelman’s Bartter’s Molecular level ↓TSC in DCT ↓NKCC, ROMK, or Cl Age at onset Teenage Children Clinical Tetany Failure to thrive Mimicked by Thiazides Loop diuretics Plasma Mg ↓ ↓ D.D. Hypocalciuria Hypercalciuria Uosm ↓
  • 67. Thiazide-induced hyponatremiaThiazide-induced hyponatremia Renal salt wasting: via TSC in DCT Water retention: hypovolemia-induced ADH release direct effect of ↑distal water reabsorption ( via PGE2↓; indomethacin↑) Magaldi et al, NDT 15: 1903-5, 2000 ↑thirst and water intake No calcium wasting
  • 68. Salt transport in DCTSalt transport in DCT TSC Na 2Cl V2R Inactive TSC dimer TSC monomer AT1R MR SPAK
  • 69. Vasopressin/CaSR in DCTVasopressin/CaSR in DCT TSC TRPV5 Na K ATP ase pH pH Na Ca 2Cl CaSR Positive PositiveCaSR CaATPase NCX V2R Kinase SPAK
  • 70.
  • 71. Salt-losing nephropathySalt-losing nephropathy Salt-losing nephropathy with inappropriate secretion of ANP( 10 ~ 47fmol/ml): no cardiac or cerebral abnormality pseudo-bartter syndrome: concentaring power highly-conserved; normokalemic metabolic alkalosis; no response to indomethacin therapy  Granulomatous interstitial nephritis&uveitis: non-caseating granuloma 6-M steroid therapy Primary renal candidiasis: caseating renal granuloma→medullary destruction
  • 72. Milk alkali syndromeMilk alkali syndrome ↑Free P-Ca++ /Mg++ CaCO3 in duodenum + ferment H+ → Free Ca++ in lumen; if low HPO4 in GI (poor intake) → Free P-Ca++ ↑ via para- cellular route Hypercalcemia GFR↓
  • 73. Anorexia nervosa + AntacidsAnorexia nervosa + Antacids Mitchell Lewis HalperinMitchell Lewis Halperin P-Na=118mM ; U-Na 44mM pH=7.2; P-HCO3=9 P-K=2.0mM; U-K=17mM K deficit >120 P-Ca 2.56mM; P-alb 2.7g/dl UV>6L; Uosm=150 P-Mg 1.5mM
  • 74.
  • 75. Shaded areas refer to changes in total body sodium because of differences in intake and excretion
  • 76. ‘skin Na+ storage’ Macrophages act as local osmo-sensors Weekly (circaseptan) patterns in sodium excretion: inversely related to aldosterone and directly to cortisol. TBNa : monthly (infradian) rhythms independent of extracellular water, body weight, or blood pressure nstead exhibited far longer ( monthly) infradian rhythms independent of ext instead exhibited far longer ( monthly) infradian rhythms independent of ex
  • 77. 23 Na-magnetic resonance imaging (MRI) can measure sodium in the skin and muscle at the calf: despite remarkable reduction in tissue Na+ content, no change in body weight was observed

Hinweis der Redaktion

  1. Osmotic gradient develops across blood brain barrier causing water to move into brain. -Two protective mechanisms: - Movement of interstitial fluid into the CSF - Loss of cellular potassium and organic osmolytes Acute hyponatremia (Na &amp;lt; 120) developing &amp;lt; 24 hours OR rate of fall of &amp;gt; 0.5 meq/L per hour: -Muscular twitching, seizures, coma Acute severe hyponatremia with CNS changes – mortality rate 50%. CPM – correction of hyponatremia faster than the brain can recover solute.
  2. Movement of water from ICF to ECF dilutes the ECF. Volume replacement with sodium containing fluids.
  3. Hyperproteinemia Multiple Myeloma Waldenstrom Macroglobulinemia
  4. Results in intracellular volume expansion with derangement of cellular function. Obtain serum and urine electrolytes Obtain plasma and urine osmolality
  5. Clinical manifestations due to volume deficit rather than hyponatremia.
  6. Unequal loss of electrolyte and water loss produces a contracted ECF volume with hyponatremia. Maintained by effect of volume depletion on kidneys inhibiting free water excretion. - Decreased GFR. - Increased proximal tubular resorption of solute and water. - Decreased deliver of fluid to the diluting segment of the nephron. - ADH released by nonosmotic stimuli.
  7. CHF – perceived as low flow state, stimulates ADH Nephrotic Syndrome – low serum protein due to urinary loss Cirrhosis – low intravascular oncotic pressure due to decreased protein production